Orbimed Advisors LLC Acquires New Position in Alto Neuroscience, Inc. (NYSE:ANRO)

Orbimed Advisors LLC bought a new position in shares of Alto Neuroscience, Inc. (NYSE:ANRO - Free Report) during the 4th quarter, according to the company in its most recent filing with the SEC. The fund bought 250,000 shares of the company's stock, valued at approximately $1,058,000. Orbimed Advisors LLC owned 0.93% of Alto Neuroscience at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the business. Price T Rowe Associates Inc. MD increased its stake in shares of Alto Neuroscience by 4.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 844,823 shares of the company's stock worth $3,575,000 after purchasing an additional 36,319 shares in the last quarter. Marshall Wace LLP acquired a new stake in Alto Neuroscience during the 4th quarter valued at $3,542,000. Northern Trust Corp boosted its stake in shares of Alto Neuroscience by 198.1% during the 4th quarter. Northern Trust Corp now owns 587,135 shares of the company's stock valued at $2,484,000 after buying an additional 390,190 shares during the last quarter. Cantor Fitzgerald L. P. acquired a new position in Alto Neuroscience in the fourth quarter worth about $1,575,000. Finally, Integral Health Asset Management LLC acquired a new position in shares of Alto Neuroscience in the 4th quarter valued at about $1,269,000.

Wall Street Analyst Weigh In

ANRO has been the topic of a number of recent analyst reports. HC Wainwright began coverage on Alto Neuroscience in a report on Monday, April 7th. They set a "buy" rating and a $10.00 price target on the stock. William Blair reiterated an "outperform" rating on shares of Alto Neuroscience in a report on Friday, March 21st. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $15.40.

Alto Neuroscience Stock Performance

NYSE ANRO opened at $2.34 on Tuesday. The stock has a market cap of $63.35 million, a P/E ratio of -0.92 and a beta of 1.87. The company has a quick ratio of 13.09, a current ratio of 13.10 and a debt-to-equity ratio of 0.05. Alto Neuroscience, Inc. has a twelve month low of $1.60 and a twelve month high of $17.55. The company's 50-day simple moving average is $2.47 and its 200 day simple moving average is $3.47.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last posted its quarterly earnings data on Thursday, March 20th. The company reported ($0.56) EPS for the quarter, topping analysts' consensus estimates of ($0.65) by $0.09. As a group, research analysts forecast that Alto Neuroscience, Inc. will post -2.54 earnings per share for the current fiscal year.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.

Want to see what other hedge funds are holding ANRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alto Neuroscience, Inc. (NYSE:ANRO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.